MedTrace Logo

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

NCT03309202 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-08-08

Study results available
· View outcomes & findings →

Summary

Hepatic impairment PK study

Conditions

  • Hepatic Impairment

Interventions

DRUG

PF-05221304

25 mg dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-19
Primary Completion
2018-06-26
Completion
2018-07-18
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Czechia
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309202 on ClinicalTrials.gov